Literature DB >> 9073053

Brachytherapy of squamous cell carcinoma of the nasal vestibule.

J F Evensen1, A B Jacobsen, J E Tausjø.   

Abstract

From 1985 to 1994, 23 patients with squamous cell carcinoma of the nasal vestibule were treated by brachytherapy. The TNM stage was as follows: T1N0 (9 patients), T2N0 (11 patients) and T4N0 (3 patients). Four patients had primary surgery and postoperative brachytherapy, whereas 12 patients had brachytherapy alone and 7 had tele- and brachytherapy in combination. For brachytherapy, the plastic tube technique was used. With the exception of one patient with a partial response, complete response was obtained in all patients. Two patients relapsed: one (T4N0) locally after 5 months and one (T2N0) regionally after 12 months. Both are alive and with no evidence of disease after salvage surgery. For early stage carcinoma (T1, T2) of the nasal vestibule, brachytherapy is a safe treatment yielding a high grade of local control and with good cosmetic results.

Entities:  

Mesh:

Year:  1996        PMID: 9073053     DOI: 10.3109/02841869609098525

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  2 in total

1.  Customized individual applicators for endocavitary brachytherapy in patients with cancers of the nasal cavity, sinonasal region and nasopharynx.

Authors:  Basel Al Kadah; Marcus Niewald; George Papaspyrou; Yvonne Dzierma; Mathias Schneider; Bernhard Schick
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-04-24       Impact factor: 2.503

2.  Interventional radiotherapy as exclusive treatment for primary nasal vestibule cancer: single-institution experience.

Authors:  Luca Tagliaferri; Nadia Carra; Valentina Lancellotta; Davide Rizzo; Calogero Casà; Giancarlo Mattiucci; Claudio Parrilla; Bruno Fionda; Francesco Deodato; Patrizia Cornacchione; Maria Antonietta Gambacorta; Gaetano Paludetti; Vincenzo Valentini; Francesco Bussu
Journal:  J Contemp Brachytherapy       Date:  2020-10-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.